Diagnostic reagents company Immuno Concepts said on Wednesday that it has passed the Histofluor Rodent LKS Rodent Tissue Slides for manual and Image Navigator use through the US Food and Drug Administration's (FDA) 510(k) process.
Following the US FDA's clearance, Histofluor Rodent Tissue Slides are available in both mouse and rat substrates and can be read manually or scanned using the innovative Image Navigator automated microscope, added the company.
The company stated the indirect immunofluorescent (IIF) test has long been the preferred method for determination of Anti-Mitochondrial Antibodies (AMA), Anti-Smooth Muscle Antibodies (ASMA) and Anti-Parietal Cell Antibodies. These autoantibodies are associated with several autoimmune diseases, including Pernicious Anemia or Autoimmune Gastritis, Primary Biliary Cholangitis (PBC) and Autoimmune Hepatitis.
According to the company, the same slides and reagents for the Histofluor Rodent Tissue Slides are used regardless of whether the slides are read manually or scanned on the Image Navigator.
In conjunction, the previously US FDA-Cleared Image Navigator eliminates the usual tedious labor of the IIF test, while still allowing the laboratory professional to control the interpretation and reporting of these tests, concluded the company.
DATROWAY receives US priority review for first-line metastatic triple negative breast cancer
Lupin launches Dasatinib tablets in US market
Natera submits Signatera CDx PMA to FDA for bladder cancer use
Pharming receives FDA complete response letter for paediatric Joenja application
Trace Biosciences' IND application for nerve-specific imaging agent approved by FDA
Frontage expands early phase clinical research capabilities across US and China
MicuRx Pharmaceuticals' IND application for MRX-5 cleared by FDA
FDA approves Tenpoint Therapeutics' YUVEZZI as first dual-agent eye drop for presbyopia
Summit Therapeutics' BLA for ivonescimab in EGFR-mutated NSCLC accepted by FDA
WuXi Biologics collaborates with Sinorda Biomedicine for antibody development
Biogen's litifilimab receives FDA Breakthrough Therapy Designation for CLE
Glaukos receives FDA approval for repeat administration of iDose TR
Guerbet's contrast agent Elucirem approved by European Commission in children from birth
Spine Innovation's LOGIC Titanium Implant System receives US FDA 510(k) market approval